BeOne Medicines Ltd (6160) AI Stock Analysis

• Market Cap: HK$279.85B
• Dividend Yield: N/A
• Average Volume (3M): 5.08M
• Price to Earnings (P/E): 124.8
• Beta (1Y): 1.05
• Revenue Growth: 49.63%
• EPS Growth: N/A
• Country: HK
• Employees: 11,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.36
• Shares Outstanding: 1,540,976,000
• 10 Day Avg. Volume: 3,608,600
• 30 Day Avg. Volume: 5,076,742
• PEG Ratio: -0.80
• Price to Book (P/B): 7.49
• Price to Sales (P/S): 6.10
• P/FCF Ratio: 34.63
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$245.32
• Price Target Upside: 34.57% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): 3.68
• Revenue Forecast (FY): HK$50.04B

• Rating: 58 Neutral
• Price Target: HK$200.00 ▲(9.71% Upside)
• Action: Reiterated Date: 03/02/26
• Date: Action: Reiterated 03/02/26

The score is primarily supported by improved financial performance in 2025 (return to profitability and strong positive free cash flow) and a solid-enough balance sheet, but it is held back by very expensive valuation (high P/E) and weak near-term technical positioning (below key moving averages with subdued momentum).

Positive Factors

Cash generation

A material operating cash flow inflection and nearly $0.94B free cash flow in 2025 indicate the business can internally fund R&D, manufacturing scale-up and commercialization. Durable cash conversion supports self-funding of launches and reduces near-term reliance on external financing.

Balance sheet strength

A sizable equity base and moderate debt-to-equity give financial flexibility for product launches, regulatory timelines and opportunistic M&A. Manageable leverage lowers refinancing pressure and supports multi-quarter execution on commercialization and late-stage trials.

Clinical/commercial momentum (ZIIHERA + TEVIMBRA)

Phase 3 OS and PFS wins for ZIIHERA with TEVIMBRA represent a structural product opportunity in first-line HER2-positive GEA. Positive pivotal data increases likelihood of label expansion, broad reimbursement and durable revenue streams via a differentiated regimen across geographies and partner channels.

Negative Factors

Earnings durability / short profit track record

Profitability is nascent after several loss-making years; a single-year inflection reduces confidence in sustained margins. Near-term operational setbacks, slower launches or pricing pressure could reverse gains given limited history of consistent earnings.

Historic cash burn and consistency risk

Despite 2025 cash generation, prior multi-year negative cash flows show execution and financing vulnerability. Renewed investment in launches or trial programs could pressure liquidity if growth stalls, making cash generation consistency a key medium-term risk.

Safety/tolerability risks for lead regimen

High rates of severe treatment-related adverse events and elevated discontinuations could limit real-world uptake, restrict eligible patient populations, increase monitoring and supportive-care costs, and complicate reimbursement negotiations despite strong efficacy.

BeOne Medicines Ltd Business Overview & Revenue Model

Company Description

BeiGene Ltd. is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

How the Company Makes Money

BeiGene generates revenue through multiple streams, primarily from the sales of its oncology therapies, which include both marketed products and those under development. The company has established partnerships and collaborations with other biopharmaceutical companies, allowing it to leverage shared resources and expertise in drug development. Additionally, BeiGene receives milestone payments and royalties from these partnerships upon achieving specific clinical or regulatory objectives. Their revenue model is bolstered by a robust pipeline of investigational drugs, which, if successful in clinical trials, can lead to substantial future earnings from both direct sales and licensing agreements.

BeOne Medicines Ltd Financial Statement Overview

Summary

Financials show a meaningful 2025 turnaround: revenue grew (~+7.6% YoY), the company returned to profitability (~5.4% net margin), and operating/free cash flow turned strongly positive. Balance sheet leverage is moderate (debt-to-equity ~0.47) with meaningful equity, but the key risk is the short track record of profits and prior multi-year losses/cash burn, which increases confidence and durability risk.

Income Statement

The income statement shows a clear profitability inflection in 2025: revenue rose to ~5.35B (+7.6% year over year) and the company turned profitable with positive operating profit and ~5.4% net margin after large losses in 2022–2024. Gross margin remains exceptionally strong (~85%), supporting the business model. The main weakness is volatility: profitability only recently returned and prior years had deeply negative operating and net margins, which raises confidence risk around the durability of earnings.

Balance Sheet

The balance sheet looks generally solid with meaningful equity (~4.36B in 2025) and moderate leverage (debt-to-equity ~0.47). While debt has increased versus prior years, leverage remains at a manageable level for the sector and assets have grown alongside the business. Key risk is that the company is coming off multiple loss-making years, which can pressure equity and financing needs if profitability slips again.

Cash Flow

Cash flow quality improved materially in 2025, with strong positive operating cash flow (~1.13B) and positive free cash flow (~0.94B), alongside very large free-cash-flow growth from the prior year. Free cash flow is robust relative to reported earnings, indicating earnings are converting well to cash. The weakness is consistency: operating and free cash flow were negative for several years leading up to 2025, indicating historical cash burn and higher execution risk if cash generation softens.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	5.35B	3.81B	2.46B	1.42B	1.18B
Gross Profit	4.56B	3.22B	2.08B	-511.06M	-447.86M
EBITDA	589.69M	-396.44M	-1.12B	-1.72B	-1.39B
Net Income	287.36M	-644.79M	-881.71M	-2.00B	-1.46B
Balance Sheet
Total Assets	8.23B	5.92B	5.81B	6.38B	8.65B
Cash, Cash Equivalents and Short-Term Investments	4.59B	2.63B	3.17B	4.53B	6.62B
Total Debt	1.09B	1.08B	930.18M	596.67M	694.64M
Total Liabilities	3.84B	2.59B	2.27B	2.00B	2.40B
Stockholders Equity	4.36B	3.33B	3.54B	4.38B	6.24B
Cash Flow
Free Cash Flow	943.13M	-669.77M	-1.75B	-1.97B	-1.61B
Operating Cash Flow	1.13B	-140.63M	-1.16B	-1.50B	-1.30B
Investing Cash Flow	-276.56M	-548.35M	60.00M	1.08B	640.66M
Financing Cash Flow	1.06B	193.45M	416.48M	-18.97M	3.64B

BeOne Medicines Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 182.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6160, the sentiment is Negative. The current price of 182.3 is below the 20-day moving average (MA) of 191.74, below the 50-day MA of 198.06, and below the 200-day MA of 187.07, indicating a bearish trend. The MACD of -7.99 indicates Positive momentum. The RSI at 36.49 is Neutral, neither overbought nor oversold. The STOCH value of 20.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6160.

BeOne Medicines Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3692	73 Outperform	HK$196.19B	12.89	16.09%	0.97%	8.68%	0.82%
2359	69 Neutral	HK$303.73B	21.89	25.65%	1.84%	11.55%	64.46%
2269	63 Neutral	HK$144.23B	10.60	9.67%	―	16.90%	63.11%
1801	61 Neutral	$145.93B	36.49	8.22%	―	52.78%	―
6160	58 Neutral	HK$279.85B	124.75	7.28%	―	49.63%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

BeOne Medicines Ltd Corporate Events

BeOne Medicines Gains Clean Swiss Audit in Voluntary Disclosure

BeOne Medicines Ltd., a Swiss-incorporated biopharmaceutical company listed in Hong Kong, has provided an update on its governance and financial reporting, highlighting an internationally experienced board led by Chairman and Executive Director John V. Oyler. The company disclosed that its Swiss statutory financial statements for the period ended December 31, 2025, have been audited by Ernst & Young AG, which issued an unqualified opinion confirming compliance with Swiss law and the firm’s articles of incorporation, with no key audit matters identified.

The voluntary release of the audited Swiss statutory accounts underlines BeOne Medicines’ emphasis on regulatory transparency and alignment with Swiss and Hong Kong market standards. The clean audit, with no significant issues flagged, supports the company’s financial reporting credibility and may reassure investors and other stakeholders about the robustness of its financial controls and compliance framework at an early stage of its listed life.

The most recent analyst rating on (HK:6160) stock is a Buy with a HK$290.00 price target. To see the full list of analyst forecasts on BeOne Medicines Ltd stock, see the HK:6160 Stock Forecast page.

BeOne Medicines Files 2025 Form 10-K, Underscoring Cross-Border Compliance

BeOne Medicines Ltd has announced that it has filed its annual report on Form 10-K for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission. The filing confirms the company’s status as a large accelerated filer, its compliance with U.S. reporting and internal control requirements, and provides updated disclosure for investors across its Nasdaq, Hong Kong and STAR Market listings.

The announcement, made in Hong Kong under the city’s listing rules, underscores BeOne Medicines’ obligations as a cross-border issuer and its adherence to parallel regulatory regimes in the United States and Hong Kong. With a non-affiliate market capitalization of about $14.7 billion as of June 30, 2025, the company’s continued timely reporting and control attestation are likely to be closely watched by global shareholders and regulators.

The most recent analyst rating on (HK:6160) stock is a Buy with a HK$290.00 price target. To see the full list of analyst forecasts on BeOne Medicines Ltd stock, see the HK:6160 Stock Forecast page.

BeOne Medicines posts 2025 results and issues cautious 2026 outlook

BeOne Medicines Ltd., a Switzerland-based biopharmaceutical group listed in Hong Kong, develops innovative drug candidates with a focus on hematology and other specialty therapies. The company is expanding globally and aligns its reporting with both U.S. GAAP and international listing standards, reflecting its dual-market regulatory and investor base.

The company released unaudited consolidated results for the fourth quarter and audited results for the full year ended 31 December 2025, along with 2026 financial guidance and business updates prepared under U.S. GAAP. Management cautioned investors that the guidance is based on preliminary assessments, may differ from IFRS-based figures to be disclosed by 31 March 2026, and should be treated carefully given clinical, regulatory and commercial risks highlighted in its risk disclosures.

The most recent analyst rating on (HK:6160) stock is a Buy with a HK$290.00 price target. To see the full list of analyst forecasts on BeOne Medicines Ltd stock, see the HK:6160 Stock Forecast page.

BeOne Medicines Sets Date for 2025 Results and Dual-Regime Reporting

BeOne Medicines Ltd. will release its fourth-quarter and full-year 2025 financial results, prepared under U.S. GAAP and SEC rules, on February 26, 2026, after Hong Kong trading hours, with the board set to review and approve the figures the same day. Management will host a live webcasted conference call that morning U.S. Eastern Time, with an archived version available on the company’s investor website.

The company also plans to publish its audited 2025 results in line with Hong Kong Stock Exchange listing rules by March 31, 2026, including a reconciliation from U.S. GAAP to IFRS and any additional required disclosures. The timetable underscores BeOne’s efforts to maintain transparency for both U.S.- and Hong Kong-focused investors and to align its reporting across multiple regulatory regimes.

The most recent analyst rating on (HK:6160) stock is a Buy with a HK$290.00 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.

BeOne Medicines Grants New RSUs to 246 Employees Under Incentive Plan

BeOne Medicines has granted 21,034 restricted share units, equivalent to 273,442 underlying shares or about 0.02% of its issued share capital, to 246 employees under its 2016 Share Option and Incentive Plan. The RSUs, which require no consideration from recipients and generally vest in 25% annual tranches over four years with potential acceleration on termination or change of control, exclude directors, chief executives and substantial shareholders, carry no performance targets or clawback, and are framed by the board’s compensation committee as market-competitive and aligned with the plan’s objectives, leaving more than 60.9 million shares available for future equity-based awards.

The most recent analyst rating on (HK:6160) stock is a Hold with a HK$219.00 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.

BeOne Medicines Grants 53,322 RSUs Under Incentive Plan to 155 Recipients

BeOne Medicines has granted 53,322 restricted share units (RSUs), equivalent to 693,186 underlying shares or about 0.04% of its issued share capital, to 155 grantees under its 2016 Share Option and Incentive Plan. The awards, which include a small allocation to an external scientific adviser, are structured to vest mainly in 25% annual tranches over four years (with certain specific vesting schedules and potential acceleration on termination or change of control), underscoring the company’s use of equity incentives to retain talent and align employees’ and advisers’ interests with long-term shareholder value while causing only minimal share dilution.

The most recent analyst rating on (HK:6160) stock is a Hold with a HK$194.00 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.

BeOne Medicines Ltd. Grants 21,274 RSUs to Employees

BeOne Medicines Ltd., a Swiss corporation listed on the Hong Kong Stock Exchange, announced the grant of 21,274 Restricted Share Units (RSUs) to 147 employees under its 2016 Share Option and Incentive Plan. This grant represents approximately 0.02% of the company’s total issued shares. The RSUs will vest over four years, subject to continued employment, with specific conditions for accelerated vesting in certain cases. This move is part of the company’s strategy to incentivize and retain talent, potentially impacting its operational efficiency and market competitiveness.

The most recent analyst rating on (HK:6160) stock is a Hold with a HK$211.00 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.